Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 17/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24942536 | 0.85 | CYP11B2 (0.55) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL16182687 | 0.85 | HDAC8 (0.34) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL1797379 | 0.85 | TRPV4 (0.59) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL3633872 | 0.83 | TRPV4 (0.41) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL15577767 | 0.83 | TRPV4 (0.44) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL9612005 | 0.81 | TRPV4 (0.55) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL4394514 | 0.80 | MAOB (0.39) | TRPV4 | |
| SCHEMBL16961654 | 0.79 | TRPV4 (0.53) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL1914223 | 0.78 | MAOA (0.34) | TRPV4 | |
| SCHEMBL14183919 | 0.75 | TSHR (0.45) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11829021-B2 | Polymer dispersed liquid crystal display device comprising a polymer network having a helical structure and method for manufacturing the same | Sharp Display Technology Corporation (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20230205010-A1 | LIQUID CRYSTAL DISPLAY ELEMENT | Sharp Display Technology Corporation (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230024383-A1 | LIQUID CRYSTAL DISPLAY DEVICE | Sharp Display Technology Corporation (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2016055947-A1 | ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| EP-0648723-B1 | Diphenylacetylene compound, process for preparing the same and liquid crystal composition and element comprising the same | SUMITOMO CHEMICAL CO (JP) | 1998-05-20 | — | — | EP | disclosed |
| US-5725797-A | Silacyclohexane compound, a process for producing the same, and a liquid crystal composition comprising the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1998-03-10 | — | — | US | disclosed |
| US-5658489-A | EXCELLENT ANISOTROPY OF REFRACTIVE INDEX; LOW VISCOSITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0648723-A1 | Diphenylacetylene compound, process for preparing the same and liquid crystal composition and element comprising the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | TRPV4 2034/4885CYP11B2 58/4885CYP11B1 42/4885 |
| US-20050080111-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | TRPV4 3079/4885CYP11B2 85/4885CYP11B1 34/4885 |
| US-20100056582-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | TRPV4 3079/4885CYP11B2 85/4885CYP11B1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.